Mounjaro vs Trulicity

Trulicity has the chemical name dulaglutide. Also made by Eli Lilly, Mounjaro is superior to Trulicity. 

Trulicity vs Mounjaro:


“Tirzepatide was superior compared with dulaglutide for glycaemic control and reduction in bodyweight. The safety profile of tirzepatide was consistent with that of GLP-1 receptor agonists, indicating a potential therapeutic use in Japanese patients with type 2 diabetes.”

“At week 52, HbA1c decreased from baseline by a least squares mean of −2·4 (SE 0·1) for tirzepatide 5 mg, −2·6 (0·1) for tirzepatide 10 mg, −2·8 (0·1) for tirzepatide 15 mg, and −1·3 (0·1) for dulaglutide. Estimated mean treatment differences versus dulaglutide were −1·1 (95% CI −1·3 to −0·9) for tirzepatide 5 mg, −1·3 (−1·5 to −1·1) for tirzepatide 10 mg, and −1·5 (−1·71 to −1·4) for tirzepatide 15 mg (all p<0·0001). Tirzepatide was associated with dose-dependent reductions in bodyweight with a least square mean difference of −5·8 kg (SE 0·4; −7·8% reduction) for 5 mg, −8·5 kg (0·4; −11·0% reduction) for 10 mg, and −10·7 kg (0·4; −13·9% reduction) for 15 mg of tirzepatide compared with −0·5 kg (0·4; –0·7% reduction) for dulaglutide.”

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

The Lancet, July/September 2022,patients%20with%20type%202%20diabetes


“Dulaglutide doses of 3.0 or 4.5 mg provided clinically relevant, dose-related improvements in HbA1c and BW with no significant treatment-by-age interactions, and with a similar safety profile across age subgroups.”

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial

Diabetes, Obesity and Metabolism, June 2021 


Mounjaro: Competing to be the Best